Graft Versus Host Disease Treatment Market: By Drug Class (Monoclonal Antibodies (Ruxolitinib, Alemtuzumab, Ibrutinib, Imatinib, Rituximab or its biosimilar, Basiliximab, Infliximab, Tocilizumab), Immunosuppressive Drugs, Steroids, Chemotherapy, Rho-associated coiled-coil–containing protein kinase 2 (ROCK2) Inhibitor (Belumosudil), Mesenchymal Stem Cells), By Disease Type (Acute, Chronic), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and By Geography

Graft Versus Host Disease Treatment Market size was valued at USD 2,967.9 million in 2023 and is poised to grow at a CAGR of 8.1% from 2024-2030.  By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF inhibitors, Tyrosine Kinase Inhibitors, and Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease and chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to be the fastest-growing segment during the forecast period. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral and parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.

Graft Versus Host Disease Treatment Market Key Developments:

• In 2023, Incyte, Jakafi® (ruxolitinib), generated USD 2.6 billion with a growth rate of 8% when compared to 2022. The company provided guidance ranging from USD 2,690 - USD 2,750 Million for FY 2024.
• In May 2022, Jakavi ruxolitinib) from Novartis has been given European Commission (EC) approval for the treatment of patients with acute or chronic GvHD who have had a poor response to corticosteroids or other systemic treatments and are 12 years of age or older.
• In Sept 2021, Ruxolitinib was approved by the US Food and Drug Administration (FDA) for the treatment of chronic Graft-versus-Host disease in patients 12 years of age and older who have failed any two conventional therapies.